Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD/DR4/B7 mouse

References

• Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221 - 9; http://dx.doi.org/10.1016/S0140-6736(01)05415-0; PMID: 11476858
   PubMed Web of Science ®Google Scholar
• Driver JP, Serreze DV, Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 2011; 33:67 - 87; http://dx.doi.org/10.1007/s00281-010-0204-1; PMID: 20424843
   PubMed Web of Science ®Google Scholar
• Chao CC, Sytwu HK, Chen EL, Toma J, McDevitt HO. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc Natl Acad Sci U S A 1999; 96:9299 - 304; http://dx.doi.org/10.1073/pnas.96.16.9299; PMID: 10430937
   PubMed Web of Science ®Google Scholar
• Preda I, McEvoy RC, Lin M, Bona CA, Rapaport R, Brumeanu TD, Casares S. Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes. Eur J Immunol 2005; 35:2762 - 75; http://dx.doi.org/10.1002/eji.200526158; PMID: 16106371
   PubMed Web of Science ®Google Scholar
• Skyler JS. Immunomodulation for type 1 diabetes mellitus. Int J Clin Pract Suppl 2010; 166:59 - 63; http://dx.doi.org/10.1111/j.1742-1241.2009.02280.x; PMID: 20377666
   PubMedGoogle Scholar
• Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32:1244 - 9; http://dx.doi.org/10.2337/dc09-0054; PMID: 19366957
   PubMed Web of Science ®Google Scholar
• Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:1573 - 9; http://dx.doi.org/10.1001/jama.2009.470; PMID: 19366777
   PubMed Web of Science ®Google Scholar
• Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008; 105:18895 - 900; http://dx.doi.org/10.1073/pnas.0810246105; PMID: 19015530
   PubMed Web of Science ®Google Scholar
• Marzorati S, Bocca N, Molano RD, Hogan AR, Doni M, Cobianchi L, Inverardi L, Ricordi C, Pileggi A. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. Transplant Proc 2009; 41:352 - 3; http://dx.doi.org/10.1016/j.transproceed.2008.09.057; PMID: 19249555
   PubMed Web of Science ®Google Scholar
• Pedotti R, Sanna M, Tsai M, DeVoss J, Steinman L, McDevitt H, Galli SJ. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 2003; 4:2; http://dx.doi.org/10.1186/1471-2172-4-2; PMID: 12597780
   PubMedGoogle Scholar
• Li L, Yi Z, Wang B, Tisch R. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J Immunol 2009; 183:4809 - 16; http://dx.doi.org/10.4049/jimmunol.0901616; PMID: 19752238
   PubMed Web of Science ®Google Scholar
• Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol 2003; 171:5587 - 95; PMID: 14607967
   PubMed Web of Science ®Google Scholar
• Casares S, Hurtado A, McEvoy RC, Sarukhan A, von Boehmer H, Brumeanu TD. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002; 3:383 - 91; http://dx.doi.org/10.1038/ni770; PMID: 11862219
   PubMed Web of Science ®Google Scholar
• Lin M, Stoica-Nazarov C, Surls J, Kehl M, Bona C, Olsen C, Brumeanu TD, Casares S. Reversal of type 1 diabetes by a new MHC II-peptide chimera: “Single-epitope-mediated suppression” to stabilize a polyclonal autoimmune T-cell process. Eur J Immunol 2010; 40:2277 - 88; http://dx.doi.org/10.1002/eji.200940094; PMID: 20540111
   PubMed Web of Science ®Google Scholar
• Casares S, Lin M, Zhang N, Teijaro JR, Stoica C, McEvoy R, Farber DL, Bona C, Brumeanu TD. A peptide-major histocompatibility complex II chimera favors survival of pancreatic beta-islets grafted in type 1 diabetic mice. Transplantation 2008; 85:1717 - 25; http://dx.doi.org/10.1097/TP.0b013e31817752cc; PMID: 18580462
   PubMed Web of Science ®Google Scholar
• Preda-Pais A, Stan AC, Casares S, Bona C, Brumeanu T-D. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes. J Autoimmun 2005; 25:21 - 32; http://dx.doi.org/10.1016/j.jaut.2005.04.003; PMID: 16005609
   PubMed Web of Science ®Google Scholar
• Casares S, Zong CS, Radu DL, Miller A, Bona CA, Brumeanu TD. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med 1999; 190:543 - 53; http://dx.doi.org/10.1084/jem.190.4.543; PMID: 10449525
   PubMed Web of Science ®Google Scholar
• Wong S, Guerder S, Visintin I, Reich E-P, Swenson KE, Flavell RA, Janeway CA Jr.. Expression of the co-stimulator molecule B7-1 in pancreatic β-cells accelerates diabetes in the NOD mouse. Diabetes 1995; 44:326 - 9; http://dx.doi.org/10.2337/diab.44.3.326; PMID: 7533734
   PubMed Web of Science ®Google Scholar
• Rajagopalan G, Kudva YC, Chen L, Wen L, David CS. Autoimmune diabetes in HLA-DR3/DQ8 transgenic mice expressing the co-stimulatory molecule B7-1 in the beta cells of islets of Langerhans. Int Immunol 2003; 15:1035 - 44; http://dx.doi.org/10.1093/intimm/dxg103; PMID: 12917255
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433 - 42; http://dx.doi.org/10.1056/NEJMoa1107096; PMID: 22296077
   PubMed Web of Science ®Google Scholar
• Casares S, Brumeanu TD. Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies. Curr Mol Med 2001; 1:357 - 78; http://dx.doi.org/10.2174/1566524013363753; PMID: 11899083
   PubMedGoogle Scholar
• Casares S, Bona CA, Brumeanu TD. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Eng 1997; 10:1295 - 301; http://dx.doi.org/10.1093/protein/10.11.1295; PMID: 9514118
   PubMedGoogle Scholar
• Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, Belunis C, Bolin DR, Arceo R, Campbell R, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996; 183:2635 - 44; http://dx.doi.org/10.1084/jem.183.6.2635; PMID: 8676084
   PubMed Web of Science ®Google Scholar